Drug Development
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
REGENXBIO
PR-01-25-NI-12Jan 14, 2025
Cell and Gene Therapy
REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
REGENXBIO
PR-M11-18-NI-028Nov 08, 2018
Licensing Agreement
REGENXBIO Announces Exclusive Worldwide License with Ultragenyx for the Treatment of CDKL5 Deficiency Disorder Using NAV Vectors
REGENXBIO
PR-M10-18-NI-093Oct 26, 2018